Revenue segments as reported by the company.

Instruments & Accessories

Systems

Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intuitive Surgical

Intuitive Surgical, Inc. engages in the development, manufacture, and marketing of da Vinci Surgical Systems, and related instruments and accessories for invasive surgery. Its products include Da Vinci and Ion. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intuitive Surgical reports robust Q4 performance and eyes future growth

Intuitive Surgical's Q4 2022 showcased strong performance and growth in procedures and system placements.
While facing challenges like macroeconomic uncertainty and supply chain costs, the company is poised for continued innovation.
Opportunities lie in expanding markets, advancing technology, and improving surgical outcomes through collaboration.
Investments in industrial scale, automation, and platform advancements signal a strategic focus on future growth.

Intuitive Surgical (ISRG) reports robust Q1 performance and growth outlook

Intuitive Surgical (ISRG) delivered strong Q1 results with revenue up 14% and exceeding procedure growth expectations.
While facing challenges in manufacturing and supply chain, the company is focusing on R&D progress and inventory replenishment.
The outlook for 2023 looks promising with increased procedure growth forecasts and a focus on improving patient outcomes and market expansion.
Overall, Intuitive Surgical (ISRG) is well-positioned to capitalize on opportunities for growth and innovation in the robotic surgery market.

Intuitive Surgical excels in Q2 performance, eyes AI opportunities

Intuitive Surgical's Q2 2023 performance showcased strong revenue growth, procedure increases, and a focus on healthcare improvement.
The company's strengths include innovative ecosystem investments, commitment to patient outcomes, and advanced surgical technologies.
Challenges include market disruptions from new drugs, expense management, and adapting to changing healthcare landscapes.
Opportunities in AI, market expansion, and new procedures position Intuitive Surgical for continued growth and innovation.

Intuitive Surgical excels in Q3, eyes global expansion and margin growth

Intuitive Surgical's Q3 performance reflects strong growth and strategic focus on innovation and market expansion. Despite challenges in specific procedure categories and pricing dynamics, the company is well-positioned to capitalize on opportunities for growth and margin improvement.

Intuitive Surgical posts strong 2023 results, da Vinci 5 launch ahead

Intuitive Surgical's 2023 performance reflects strong revenue growth, operational excellence, and a strategic focus on innovation with the upcoming da Vinci 5 launch.
While facing challenges in operating margin pressure and supply chain issues, the company is well-positioned to capitalize on opportunities in soft tissue surgery, big data integration, and leased placements.
Investors should monitor how Intuitive Surgical navigates the launch of da Vinci 5, manages operational challenges, and leverages growth opportunities to sustain its market leadership.
Overall, Intuitive Surgical's Q4 earnings call highlights a resilient business model, customer-centric approach, and a commitment to advancing surgical technology for better patient outcomes.

Intuitive Surgical posts robust Q1 results amidst global market challenges

Intuitive Surgical delivered strong Q1 results with notable procedure and revenue growth, despite challenges in certain markets.
The company's focus on newer platforms, operational efficiency, and strategic outlook for 2024 positions it for continued success.
Addressing challenges and seizing opportunities in global markets and product innovation will be key for sustained growth and competitiveness.

Intuitive Surgical excels in Q2, eyes global expansion and innovation

Intuitive Surgical's Q2 performance reflects strength in procedure growth and system platform advancements.
The company's commitment to innovation and value creation positions them well for future success.
Challenges include sustaining margins and navigating market dynamics, while opportunities lie in expansion and innovation.
Overall, Intuitive Surgical's focus on growth, technology, and patient care sets a positive trajectory for the future.

Intuitive Surgical excels in Q3 with strong growth and innovation

Intuitive Surgical's Q3 2024 performance reflects a company in a strong position with notable achievements in procedures, financials, and technological advancements. While facing challenges in margin progression and international expansion, the company is well-positioned to leverage opportunities in innovation and customer insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Shares of Intuitive Surgical (ISRG) hit an all-time high Friday, a day after the medical device maker posted better-than-expected results on more use of its da Vinci minimally invasive surgical devices.

Intuitive Surgical Stock Hits Record High on da Vinci Device Demand

ISRG's third-quarter results reflect a healthy demand for procedures. Higher pricing boosts procedure sales.

Intuitive Surgical Q3 Earnings Beat, Procedures Robust

Netflix

Major indexes faded late in Thursday's trading, with the Nasdaq Composite finishing up just .036%.

Live Market Updates: Nasdaq Composite Up | NFLX & ISRG Crush Earnings

I reiterate a 'Sell' rating on Intuitive Surgical with a fair value of $350 per share due to its hefty valuation. The Da Vinci 5 robot rollout in mid-2025 is a major catalyst, with significant growth potential from innovative technology and positive surgeon feedback. Despite strong leadership and market position, ISRG's overvaluation and high WACC of 13% justify the 'Sell' rating.

Intuitive Surgical Q3: Da Vinci 5 Robot Set For 2025, But Overvalued

Intuitive Surgical, Inc. (NASDAQ:ISRG ) Q3 2024 Earnings Conference Call October 17, 2024 4:30 PM ET Company Participants Brandon Lamb - Investor Relations Gary Guthart - Chief Executive Officer Dave Rosa - President Jamie Samath - Chief Financial Officer Conference Call Participants Travis Steed - Bank of America Larry Biegelsen - Wells Fargo Robbie Marcus - JPMorgan David Roman - Goldman Sachs Rick Wise - Stifel Adam Maeder - Piper Sandler Brandon Vazquez - William Blair Matt Miksic - Barclays Operator Thank you everyone for standing by and welcome to the Intuitive Third Quarter 2024 Earnings Release. Now at this time all participants are on a listen-only mode.

Intuitive Surgical, Inc. (ISRG) Q3 2024 Earnings Call Transcript

Earnings of $5.40 per share for NFLX surged past the $5.09 in the Zacks consensus, demonstrating +45% growth year over year.

Netflix, Intuitive Beat Q3 Earnings Easily

Intuitive Surgical, Inc. (ISRG) came out with quarterly earnings of $1.84 per share, beating the Zacks Consensus Estimate of $1.65 per share. This compares to earnings of $1.46 per share a year ago.

Intuitive Surgical, Inc. (ISRG) Beats Q3 Earnings and Revenue Estimates

The robotic surgery leader reported strong Q3 results.

Intuitive Surgical's Revenue Surges 17%

Medical device maker Intuitive Surgical beat Wall Street estimates for third-quarter profit on Thursday, helped by strong demand for its surgical robots used in minimally invasive procedures, sending shares up 6% in extended trading.

Intuitive beats quarterly profit estimates on strong demand for surgical robots

Shares of Intuitive Surgical Inc. jumped after hours on Thursday after the company reported third-quarter results that beat Wall Street's expectations, helped by wider adoption of its robotic-surgery equipment.

Intuitive Surgical's stock rises after third-quarter results beat on jump in robotic surgeries

Intuitive Surgical stock is flirting with its 50-day line as the robotic surgery behemoth approaches its third-quarter report late Thursday.

Intuitive Surgical's Earnings Are On Deck. Will Its 41% Surge Remain Intact?

Intuitive Surgical scheduled to report earnings after Thursday's close. The stock hit a record high of $496.48/share in 2024 and, as of this writing, it is currently trading near $474.

Earnings Preview: What To Expect From Intuitive Surgical

Travelers

Taiwan Semiconductor Manufacturing

Victoria's Secret & Co

Many stocks in the Russell 2000 are small community banks, and we've seen big banks perform very well overall so far in Q3 earnings season.

Small-Cap Russell Dominates Stock Market Hump Day

Intuitive Surgical (ISRG) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Intuitive Surgical (ISRG) Beat Estimates Again in Its Next Earnings Report?

Intuitive Surgical (NASDAQ: ISRG) will report its Q3 2024 results on Thursday, October 17. We expect the company's revenues to come in at $2 billion and adjusted earnings to be $1.60 per share, reflecting a top-line above, but earnings slightly below the consensus estimate.

Intuitive Surgical Q3'24 Earnings Preview

Intuitive Surgical's third-quarter results are likely to reflect solid performance in the company's Instruments & Accessories segment. Improving margins buoy optimism.

Should ISRG Stock Be Part of Your Portfolio Ahead of Q3 Earnings?

Besides Wall Street's top -and-bottom-line estimates for Intuitive Surgical (ISRG), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.

Intuitive Surgical (ISRG) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates

AI Leader Taiwan Semiconductor is also on the earnings calendar, along with more financial stocks like American Express.

Earnings Calendar Spotlight On Netflix, Intuitive Surgical — And This AI Leader

Dell Technologies

These stocks are on a winning streak, but there's always more for investors to consider than stock price.

2 Soaring Growth Stocks Up 45% and 60% in 2024 to Buy Right Now

In the latest trading session, Intuitive Surgical, Inc. (ISRG) closed at $490.38, marking a +2% move from the previous day.

Intuitive Surgical, Inc. (ISRG) Outperforms Broader Market: What You Need to Know

ISRG stock has maintained an uptrend so far this year on the back of robust da Vinci portfolio performance. However, the stock has declined in the past month.

Intuitive Surgical Stock Declines 0.7% in a Month: Is It Losing Steam?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Wall Street Analysts See Intuitive Surgical (ISRG) as a Buy: Should You Invest?

In this article, we will take a look into Intuitive Surgical Inc's (ISRG, Financial) DCF analysis, a reliable and data-driven approach to estimating its intrinsic value. Instead of using future free cash flow as in the traditional DCF model, the GuruFocus DCF calculator uses EPS without NRI as the default for the DCF model based on research that shows that historically stock prices have been more correlated with earnings than free cash flow.

Unlocking Intrinsic Value: Analysis of Intuitive Surgical Inc

Eli Lilly

Momentum investing is based on the idea that stocks that have risen recently will tend to keep rising and that stocks that have fallen tend to keep falling. In 1993, researchers Narasimhan Jegadeesh and Sheridan Titman at UCLA brought the idea forward.

3 Momentum Trades Too Good Pass Up

In the closing of the recent trading day, Intuitive Surgical, Inc. (ISRG) stood at $484.76, denoting a -1.33% change from the preceding trading day.

News for Intuitive Surgical Stock (ISRG)